2003 Disease Therapies Vaccine 
The Pharma Data
JULY 22, 2021
NOTE: ADUHELM TM (aducanumab-avwa)injection 100 mg/mL solutionis indicated for the treatment of Alzheimer’s disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
The Pharma Data
FEBRUARY 12, 2022
The approval extends the current indication in China as add-on therapy in adults and children aged five years and older with active systemic lupus erythematosus (SLE). Belimumab is also approved in China for five-year-old and older patients with active, autoantibody-positive SLE with high disease activity (e.g., About lupus.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NIH Director's Blog: Drug Development
MAY 21, 2020
Science, 2020 We now know that the immune system of nearly everyone who recovers from COVID-19 produces antibodies against SARS-CoV-2, the novel coronavirus that causes this easily transmitted respiratory disease [1]. So, what exactly led up to this latest scientific achievement? In the U.S.
The Pharma Data
MARCH 26, 2021
It causes inflammation in the kidneys and can lead to end-stage kidney disease which may require dialysis or a transplant. The adverse reactions observed in BLISS-LN were consistent with the known safety profile of Benlysta administered intravenously plus standard therapy in patients with SLE. About the BLISS-LN study.
The Pharma Data
MAY 5, 2021
GlaxoSmithKline plc (GSK) today announced the European Commission has approved the expanded use of intravenous and subcutaneous BENLYSTA (belimumab) in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis (LN) in Europe, in addition to systemic lupus erythematosus (SLE).
The Pharma Data
DECEMBER 23, 2020
AIM announced in October that the myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) clinical trial received IRB approval to include patients previously diagnosed with SARS-CoV-2 – which causes the disease COVID-19 – but who now demonstrate post-acute infection chronic fatigue-like symptoms. development pipeline for ME/CFS.
Drug Target Review
NOVEMBER 30, 2023
From an early age, I’ve been passionate about finding cures for difficult-to-treat diseases. Then I was approached to co-found AC Immune in 2003. I accepted and I’ve been CEO ever since; our goal, from the beginning, was to pioneer new ways to diagnose, treat and prevent neurodegenerative diseases.
Expert insights. Personalized for you.
52 
Let's personalize your content